Notice of Intent to Sole Source – LabCorp

This acquisition is for Laboratory Testing Services at the National Institutes of Health (NIH) Clinical Center (CC) Department of Pediatrics. • Product Service Code: Q301 – Laboratory Testing • NAICS Code: 541380 – Testing Laboratories and Services • Place of Performance: Bethesda, MD 20892 USA POTS: 25-000086 Description: This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institutes of Health (NIH) intends to award a fixed price purchase order to Laboratory Corporation of America, located at 231 Maple Ave, Burlington, NC, on a firm fixed price sole source award basis to provide laboratory tetsting services to the National Institutes of Health. It is essential to measure 11-oxo-androgens, newly available biomarkers for adrenal disorders, for this clinical research protocol. LabCorp is the only commercial laboratory that measures an 11-oxo-androgen panel, which measures 11-hydroxyandrostenedione, 11-hydroxytestosterone and 11-ketotestosterone. In addition, the NIH Clinical Center Department of Pediatrics has utilized LabCorp for genetic testing for CAH due to 21-hydroxylase deficiency since 2004. Changing to a different lab could potentially compromise the natural history protocol genetic evaluation of CAH. Switching laboratories could necessitate other testing to be performed on historical data, which would increase the cost to the government and potentially impair clinical care. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by Jan. 5, 2026 at 12pm EST.